A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00431873
Recruitment Status : Completed
First Posted : February 6, 2007
Last Update Posted : July 1, 2015
Information provided by (Responsible Party):
Mirati Therapeutics Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : November 2008
  Study Completion Date : November 2008
  Certification/Extension First Submitted : June 4, 2015